India Diabetes Care Devices Market Outlook to 2025 - Glucose Monitoring and Insulin Delivery

Table of Contents

• 1.1 List of Tables 4
• 1.2 List of Figures 4

2 Introduction 6

• 2.1 What Is This Report About? 6
• 2.2 Diabetes Care Devices Market Segmentation 6
• 2.3 Definitions of Markets Covered in the Report 7

3 Diabetes Care Devices Market, India 9

• 3.1 Diabetes Care Devices Market, India, Revenue ($m), 2015-2025 9
• 3.2 Diabetes Care Devices Market, India, Revenue Mix ($m), 2019 11
• 3.3 Diabetes Care Devices Market, India, Category Contribution by Revenue ($m), 2019 12
• 3.4 Diabetes Care Devices Market, India, Revenue ($m), 2015-2025 13
• 3.5 Diabetes Care Devices Market, India, Volume (Units), 2015-2025 15
• 3.6 Diabetes Care Devices Market, India, Volume (Units), 2015-2025 17
• 3.7 Diabetes Care Devices Market, India, Company Share by Revenue ($m), 2019 19

4 Glucose Monitoring Market, India 21

• 4.1 Glucose Monitoring Market, India, Revenue ($m), 2015-2025 21
  • 4.1.1 Blood Glucose Meters Market, India, Revenue ($m), by Segment, 2015-2025 23
• 4.2 Glucose Monitoring Market, India, Volume (Units), 2015-2025 25
  • 4.2.1 Blood Glucose Meters Market, India, Volume (Units), by Segment, 2015-2025 27
• 4.3 Glucose Monitoring Market, India, Average Price ($), 2015-2025 29
• 4.4 Glucose Monitoring Market, India, Distribution Share by Revenue ($m), 2019 30
• 4.5 Glucose Monitoring Market, India, Company Share by Revenue ($m), 2019 31

5 Insulin Delivery Market, India 32

• 5.1 Insulin Delivery Market, India, Revenue Mix ($m), 2019 32
• 5.2 Insulin Delivery Market, India, Segment Contribution (%), 2019 33
• 5.3 Insulin Delivery Market, India, Revenue ($m), 2015-2025 34
  • 5.3.1 Insulin Pens Market, India, Revenue ($m), by Segment, 2015-2025 36
  • 5.3.2 Insulin Pumps Market, India, Revenue ($m), by Segment, 2015-2025 38
• 5.4 Insulin Delivery Market, India, Volume (Units), 2015-2025 40
  • 5.4.1 Insulin Pens Market, India, Volume (Units), by Segment, 2015-2025 42
  • 5.4.2 Insulin Pumps Market, India, Volume (Units), by Segment, 2015-2025 44
• 5.5 Insulin Delivery Market, India, Average Price ($), 2015-2025 46
• 5.6 Insulin Delivery Market, India, Distribution Share by Revenue ($m), 2019 47
• 5.7 Insulin Delivery Market, India, Company Share by Revenue ($m), 2019 48

6 Overview of Key Companies in India, Diabetes Care Devices Market 50

• 6.1 DexCom Inc 50
  • 6.1.1 Company Overview 50
• 6.2 Novo Nordisk AS 50
  • 6.2.1 Company Overview 50
• 6.3 Medtronic Plc 50
  • 6.3.1 Company Overview 50
• 6.4 Abbott Laboratories 51
  • 6.4.1 Company Overview 51
• 6.5 Sanofi 51
  • 6.5.1 Company Overview 51
• 6.6 Eli Lilly and Co 51
  • 6.6.1 Company Overview 51
• 6.7 F. Hoffmann-La Roche Ltd 52
  • 6.7.1 Company Overview 52
• 6.8 Insulet Corp 52
  • 6.8.1 Company Overview 52

7 Diabetes Care Devices Market Pipeline Products 53

8 Financial Deals Landscape 54

• 8.1 Debt Offerings 54
  • 8.1.1 Piramal Enterprises Raises USD99.5 Milion in Private Placement of 10.25% Debentures Due 2021 54
  • 8.1.2 Piramal Enterprises to Raise up to USD247 Million in Private Placement of Convertible Debentures 55
• 8.2 Equity Offerings 57
  • 8.2.1 Piramal Enterprises Raises USD515.7 Million in Rights Offering of Shares 57

9 Recent Developments 59

• 9.1 Corporate Communications 59
  • 9.1.1 Dec 03, 2019: Siddharth Mittal takes over as CEO and Joint Managing Director of Biocon 59
• 9.2 Financial Announcements 59
  • 9.2.1 Feb 04, 2020: Piramal Enterprises announces consolidated results for Q3 & 9M FY2020 ended December 31, 2019 59
  • 9.2.2 Oct 23, 2019: Biocon Q2FY20 earnings revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3% 61
  • 9.2.3 Oct 21, 2019: Piramal Enterprises announces consolidated results for the second quarter & half year ended September 30, 2019 65
  • 9.2.4 Oct 16, 2019: Abbott reports third-quarter 2019 results 65
  • 9.2.5 Jul 30, 2019: Piramal Enterprises announces consolidated results for the quarter ended June 30, 2019 68
  • 9.2.6 Jul 25, 2019: Biocon Q1FY 20 revenue rs 1,490Cr, up 25%; EBITDA up 51% at rs 462Cr 68
  • 9.2.7 Apr 25, 2019: Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr 71
• 9.3 Legal And Regulatory 73
  • 9.3.1 Feb 27, 2020: Biocon's small molecules API manufacturing facility completes post - approval and GMP U.S. FDA inspection 73
  • 9.3.2 Feb 22, 2020: Biocon's insulin manufacturing facility in Malaysia completes U.S. FDA (PAI) inspection 74
  • 9.3.3 Jan 20, 2020: Biocon's oral solid dosage manufacturing facility completes pre-approval U.S. FDA inspection with zero observations 74
  • 9.3.4 Nov 05, 2019: Biocon’s Biologics Drug Products facility in Bengaluru receives EIR from U.S. FDA 74
  • 9.3.5 Sep 20, 2019: U.S. FDA completes pre-approval inspection of two new Biocon Biologics facilities in Bengaluru 75
  • 9.3.6 Jul 08, 2019: Pre -Approval U.S. FDA Inspection Conducted at Biocon's Insulins Facilities in Malaysia 75
  • 9.3.7 Jul 08, 2019: Biocon provides update on FDA inspection of its insulin facilities in Malaysia 75
  • 9.3.8 Jun 14, 2019: Biocon Biologics facilities In Bengaluru receive EU GMP Certification 76
• 9.4 Other Significant Developments 76
  • 9.4.1 Dec 12, 2019: HemoCue, the pioneer and global leader in Hemoglobin point-of-care testing to further strengthen National Activities in the Combat against Anemia in India 76
  • 9.4.2 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI 77
  • 9.4.3 May 23, 2019: Ypsomed increases EBIT and invests in long-term profitability 78

10 Appendix 81

• 10.1 Research Methodology 82
  • 10.1.1 Coverage 82
  • 10.1.2 Secondary Research 82
  • 10.1.3 Primary Research 83
  • 10.1.4 Market Modeling and Forecasting 83
  • 10.1.5 Company Share Analysis 85
  • 10.1.6 Distribution Share Analysis 85
  • 10.1.7 Benchmarking 86
• 10.2 GlobalData Consulting 86
• 10.3 Contact Us 87